Your browser is no longer supported. Please, upgrade your browser.
UBX Unity Biotechnology, Inc. daily Stock Chart
UBX [NASD]
Unity Biotechnology, Inc.
Index- P/E- EPS (ttm)-1.86 Insider Own9.00% Shs Outstand49.66M Perf Week-3.53%
Market Cap200.27M Forward P/E- EPS next Y-1.53 Insider Trans0.07% Shs Float44.10M Perf Month5.51%
Income-86.40M PEG- EPS next Q-0.49 Inst Own67.60% Short Float7.51% Perf Quarter-55.67%
Sales- P/S- EPS this Y30.30% Inst Trans-0.13% Short Ratio2.01 Perf Half Y-42.49%
Book/sh2.26 P/B1.69 EPS next Y30.10% ROA-56.20% Target Price5.67 Perf Year-45.44%
Cash/sh2.29 P/C1.68 EPS next 5Y- ROE-76.30% 52W Range2.72 - 15.44 Perf YTD-46.88%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-75.19% Beta-
Dividend %- Quick Ratio7.90 Sales past 5Y- Gross Margin- 52W Low40.81% ATR0.26
Employees100 Current Ratio7.90 Sales Q/Q- Oper. Margin- RSI (14)56.47 Volatility6.25% 6.43%
OptionableYes Debt/Eq0.00 EPS Q/Q32.60% Profit Margin- Rel Volume0.39 Prev Close3.97
ShortableYes LT Debt/Eq0.00 EarningsJul 31 AMC Payout- Avg Volume1.64M Price3.83
Recom2.80 SMA203.57% SMA50-10.81% SMA200-41.01% Volume639,893 Change-3.53%
Aug-18-20Downgrade Morgan Stanley Overweight → Equal-Weight $5
Aug-18-20Downgrade Mizuho Buy → Neutral $33 → $4
Aug-18-20Downgrade Citigroup Buy → Neutral $31 → $5
Aug-17-20Downgrade ROTH Capital Buy → Neutral
Jul-28-20Initiated ROTH Capital Buy $35
Dec-12-19Initiated Cantor Fitzgerald Overweight $20
Mar-07-19Initiated Cantor Fitzgerald Overweight $21
Sep-07-18Initiated Mizuho Buy
May-29-18Initiated Morgan Stanley Overweight $25
May-29-18Initiated Goldman Neutral $17
May-29-18Initiated Citigroup Buy $32
Oct-12-20 08:00AM  
Sep-15-20 08:00AM  
Sep-04-20 08:00AM  
Aug-31-20 04:05PM  
Aug-25-20 08:39AM  
Aug-18-20 09:21AM  
Aug-17-20 01:49PM  
11:32AM  
11:12AM  
07:00AM  
Aug-04-20 04:05PM  
Jul-31-20 07:57AM  
Jul-29-20 04:05PM  
Jul-24-20 08:00AM  
Jul-06-20 05:00PM  
Jul-02-20 08:21AM  
Jul-01-20 04:05PM  
Jun-11-20 02:32PM  
Jun-08-20 09:04AM  
Jun-05-20 01:11PM  
May-28-20 04:05PM  
May-07-20 04:05PM  
May-04-20 04:30PM  
Apr-27-20 11:06AM  
Apr-20-20 08:24AM  
Mar-31-20 04:05PM  
Mar-30-20 05:20PM  
Mar-11-20 04:05PM  
Mar-03-20 04:05PM  
Mar-02-20 04:30PM  
Feb-25-20 06:00AM  
Feb-24-20 04:05PM  
Jan-30-20 01:49PM  
Dec-22-19 05:09PM  
Nov-06-19 04:05PM  
Oct-31-19 02:14PM  
08:00AM  
Oct-24-19 08:00AM  
Oct-23-19 03:29PM  
08:00AM  
Sep-20-19 08:00AM  
Aug-27-19 08:00AM  
Aug-23-19 12:50PM  
Aug-22-19 10:09AM  
Aug-07-19 04:05PM  
Jul-30-19 04:30PM  
08:00AM  
Jun-18-19 02:47PM  
07:00AM  
May-30-19 07:33AM  
May-29-19 04:05PM  
May-23-19 04:01PM  
09:19AM  
May-22-19 07:21AM  
May-11-19 10:43AM  
May-08-19 04:05PM  
Apr-29-19 04:05PM  
Mar-06-19 08:00AM  
Mar-04-19 04:05PM  
Feb-27-19 04:05PM  
Feb-25-19 04:05PM  
Jan-23-19 07:22AM  
Jan-22-19 04:05PM  
Jan-08-19 07:00AM  
Jan-03-19 04:52PM  
Dec-05-18 10:35AM  
08:46AM  
Dec-04-18 08:00AM  
07:59AM  
Dec-03-18 05:30PM  
Nov-13-18 08:00AM  
Nov-07-18 04:05PM  
Oct-31-18 04:05PM  
Oct-01-18 01:34PM  
Sep-24-18 04:05PM  
Sep-20-18 02:59PM  
Sep-17-18 08:00AM  
Sep-14-18 09:53AM  
Sep-13-18 02:46PM  
Sep-05-18 04:05PM  
Aug-29-18 09:39AM  
Aug-09-18 04:05PM  
Jul-31-18 04:05PM  
Jul-13-18 02:45PM  
Jun-25-18 08:00AM  
Jun-13-18 04:00PM  
07:20AM  
Jun-07-18 05:00PM  
Jun-05-18 04:05PM  
10:00AM  
May-29-18 04:05PM  
04:04PM  
May-14-18 04:05PM  
10:32AM  
May-07-18 04:05PM  
May-04-18 12:45AM  
May-03-18 04:37PM  
May-02-18 07:10PM  
12:45PM  
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
David Nathaniel EPresidentJun 05Buy8.903,20028,4782,327,186Jun 09 04:44 PM
Goeltz II Robert C.Chief Financial OfficerFeb 24Option Exercise3.4310,00034,300134,404Feb 26 05:48 PM